pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
GLP-1 receptor · news · pharmadog
← back to GLP-1 receptor
News · GLP-1 receptor
471
stories
Jul 23, 26
STAT+: What’s in the last-minute flurry of health care bills?
stat
Jul 23, 26
A father’s mission to save his daughter, and allegations on telehealth GLP-1 prescribing
stat
Jul 23, 26
STAT+: Pharmalittle: We’re reading about Lilly obesity drug data, a push for FDA to ban DTC ads, and more
stat
Jul 23, 26
STAT+: HHS to convene experts on standards for clinical AI
stat
Jul 23, 26
STAT+: FDA is urged by advocacy group to ban DTC prescription drug ads
stat
Jul 23, 26
Lilly preps FDA run for ‘triple-G’ weight loss drug with Phase 3 data
biospace
Jul 23, 26
Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add on
biospace
Jul 23, 26
STAT+: New data on Eli Lilly’s ‘triple-G’ drug leave open questions on heart benefit
stat
Jul 23, 26
Exclusive: Obesity biotech Verdiva hires ex-Metsera CMO as crucial readouts near
endpoints
Jul 23, 26
Lilly’s triple-G drug hits 22.6% weight loss, but impact on reducing cardio risk is less clear
fiercebiotech
Jul 23, 26
Roche drops TCE for lupus, but hasn’t given up on autoimmune cell therapies
fiercebiotech
Jul 22, 26
STAT+: Pharmalittle: We’re reading about Trump’s plan for tariffs on generics, a Merck and Gilead HIV pill, and more
stat
Jul 22, 26
Wainua flop narrows AstraZeneca’s path to $80B goal ahead of high-risk readouts
biospace
Jul 21, 26
Novo sues Lilly over 'deceptive' ads comparing GLP-1 drug doses
endpoints
Jul 21, 26
Samsung Biologics targets $1.8B PolyPeptide buyout to expand in obesity
biospace
Jul 21, 26
Novo sues Lilly, alleging ‘misleading’ advertising of obesity drugs
biopharma dive
Jul 21, 26
Is there an exodus underway at Epic?
stat
Jul 21, 26
STAT+: Anthropic deepens work with rare disease drugs
stat
Jul 21, 26
STAT+: Pharmalittle: We’re reading about Novo suing Lilly over ‘deceptive’ ads, a fugitive’s secret life in biotech, and more
stat
Jul 21, 26
STAT+: Nabla’s new CEO on plan to gain market share in a competitive AI scribe environment
stat
Jul 21, 26
STAT+: Novo Nordisk sues Eli Lilly over GLP-1 drug ads it calls ‘deceptive’
stat
Jul 20, 26
STAT+: Pharmalittle: We’re reading about a telehealth firm and patient safety, PBMs overcharging, and more
stat
Jul 20, 26
HHS vaccine committee quietly gets new charter
stat
Jul 20, 26
Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide maker
biopharma dive
Jul 20, 26
STAT+: Telemedicine company touted by Novo Nordisk stressed profits over patient safety, ex-workers say
stat
Jul 20, 26
Type 1 diabetes pipeline making ‘remarkable progress’ toward insulin independence
biospace
Jul 18, 26
Opinion: STAT readers on the value of primary care, obesity as a disease, and more
stat
Jul 17, 26
Compounders maintain a firm grip on the GLP-1 market
biopharma dive
Jul 16, 26
STAT+: Medicare wants to shake up how it pays for clinical AI
stat
Jul 16, 26
STAT+: Eli Lilly to acquire psychedelics-focused biotech AtaiBeckley
stat
← prev
page 12 of 16
next →